期刊
JOURNAL OF PHARMACEUTICAL ANALYSIS
卷 11, 期 5, 页码 541-554出版社
ELSEVIER
DOI: 10.1016/j.jpha.2020.07.005
关键词
Artemisinin resistance; Quiescence; K13 mutations; Non-K13 mutations; Artemisinin-based combination therapy p (ACT) failure; Drugs in development; Malaria eradication
资金
- ICGEB Arturo Falaschi Pre-doctoral fellowship
Cambodia switched from dihydroartemisinin-piperaquine to artesunate-mefloquine as first-line therapy due to parasite resistance, but now faces triple mutant strains, indicating the need for alternative treatment strategies. Proper understanding of contributors to artemisinin resistance is essential for identifying novel strategies to combat resistance and protect future antimalarial drugs.
Having faced increased clinical treatment failures with dihydroartemisinin-piperaquine (DHA-PPQ), Cambodia swapped the first line artemisinin-based combination therapy (ACT) from DHA-PPQ to artesunate-mefloquine given that parasites resistant to piperaquine are susceptible to mefloquine. However, triple mutants have now emerged, suggesting that drug rotations may not be adequate to keep resistance at bay. There is, therefore, an urgent need for alternative treatment strategies to tackle resistance and prevent its spread. A proper understanding of all contributors to artemisinin resistance may help us identify novel strategies to keep artemisinins effective until new drugs become available for their replacement. This review highlights the role of the key players in artemisinin resistance, the current strategies to deal with it and suggests ways of protecting future antimalarial drugs from bowing to resistance as their predecessors did. (c) 2020 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据